PATENT CLAIM ANALYSIS

Application Number: 15994502
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-03
Patent Classification: ["514", "183000"]

Abstract:
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

Claim (Index 48):
The composition of  claim 47  wherein the additional therapeutic agent is selected from the group consisting of:\n (a) at least one agent inducing immunoactivity, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (b) at least one agent inducing macrophage activation, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (c) at least one cytokine, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (d) at least one agent inhibiting telomerase, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (e) at least one agent inhibiting survivin, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (f) at least one agent inducing demethylation, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (g) at least one adjuvant, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (h) at least one antibody, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (i) at least one innate or adaptive immune stimulator, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (j) at least one checkpoint inhibitor, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (k) at least one mTOR antagonist, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (l) at least one Akt inhibitor, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (m) at least one notch inhibitor, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (n) at least one HSP inhibitor, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (o) at least one phosphatidylinositide 3-kinase inhibitor, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (p) at least one kinase inhibitor, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (q) cytarabine, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (r) taxane, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (s) taxol, wherein the bisantrene or the derivative or analog of bisantrene is used as a chemotherapeutic agent; \n (p) at least one agent inducing telomerase inhibition, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; \n (t) at least one cytokine, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; \n (u) at least one agent inhibiting survivin, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; \n (v) at least one agent inducing demethylation, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; \n (w) at least one adjuvant, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; \n (x) at least one antibody, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; \n (y) at least one innate or adaptive immune stimulator, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; \n (z) at least one checkpoint inhibitor, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; \n (aa) at least one mTOR antagonist, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; \n (ab) at least one Akt inhibitor, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; \n (ac) at least one notch inhibitor, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; \n (ad) at least one HSP inhibitor, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; \n (ae) at least one phosphatidylinositide 3-kinase inhibitor, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; \n (af) at least one kinase inhibitor, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; \n (ag) cytarabine, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; \n (ah) taxane, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation; and \n (ai) taxol, wherein the bisantrene or the derivative or analog of bisantrene is used as an agent inducing macrophage activation.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.31579
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15979041', '14907728', '14907729', '13817096', '14250958']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8177913867400914
- 35 USC 102 Novelty (BERT): 0.5309105838005518
- Combined Prediction Score: 0.7891033064461375
- Mean Citation Score: 276.52593
- Max Citation Score: 362.98706
- Similarity Product: 250.5766268871546

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test